Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for glioma susceptibility 4 has been reported in the published literature.
No clinical trials have been registered for glioma susceptibility 4.
98 publications have been identified in PubMed for glioma susceptibility 4. Research spans Diagnostic / Biomarker (28%), Basic Science / Preclinical (27%), and Epidemiology / Natural History (22%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 27 | 28% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:59 PM UTC
Online Mendelian Inheritance in Man
Laboratory research
26 |
27% |
Disease patterns and progression | 22 | 22% |
Research summaries | 7 | 7% |
Patient case studies | 6 | 6% |
New treatment approaches | 6 | 6% |
Clinical study results | 4 | 4% |
Park M (2026). [PMID: 42232602](https://pubmed.ncbi.nlm.nih.gov/42232602/). *Oncol Res*. [Epidemiology / Natural History]
Zheng Y (2026). [PMID: 40083086](https://pubmed.ncbi.nlm.nih.gov/40083086/). *Cancer research and treatment*. [Basic Science / Preclinical]
Debiasi G (2026). [PMID: 41368710](https://pubmed.ncbi.nlm.nih.gov/41368710/). *Journal of magnetic resonance imaging : JMRI*. [Diagnostic / Biomarker]
Vazzano Goldstone J (2026). [PMID: 41572278](https://pubmed.ncbi.nlm.nih.gov/41572278/). *Diagnostic pathology*. [Review / Meta-Analysis]
Maurya S (2026). [PMID: 41894128](https://pubmed.ncbi.nlm.nih.gov/41894128/). *Magma (New York, N.Y.)*. [Diagnostic / Biomarker]
Gu L (2026). [PMID: 41182115](https://pubmed.ncbi.nlm.nih.gov/41182115/). *The International journal of neuroscience*. [Gene Therapy / Novel Therapeutics]
DiNardo CD (2026). [PMID: 41686515](https://pubmed.ncbi.nlm.nih.gov/41686515/). *Cancer*. [Epidemiology / Natural History]
Cobb DA (2026). [PMID: 41793303](https://pubmed.ncbi.nlm.nih.gov/41793303/). *Molecular cancer therapeutics*. [Basic Science / Preclinical]
Li X (2026). [PMID: 41368683](https://pubmed.ncbi.nlm.nih.gov/41368683/). *Journal of magnetic resonance imaging : JMRI*. [Diagnostic / Biomarker]
Selig M (2026). [PMID: 41220108](https://pubmed.ncbi.nlm.nih.gov/41220108/). *FEBS open bio*. [Basic Science / Preclinical]
AI-curated news mentioning glioma susceptibility 4
Updated Aug 25, 2026
A new study presents a self-assembled nano-multiple warheads platform designed for precise targeting in combinatorial chemotherapy, photothermal therapy (PTT), and photodynamic therapy (PDT) against glioma. This innovative approach could enhance treatment efficacy for patients with this challenging brain tumor.
The National Cancer Institute is offering licenses for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H. These cell lines, derived from the same patient pre- and post-malignant transformation, present a unique opportunity for research into glioma progression and treatment resistance.
A study evaluates the effectiveness of integrated (18)F-FET PET/MR fusion for preoperative assessment of IDH status in adult glioma. The research compares various fusion algorithms, potentially enhancing diagnostic accuracy for glioma patients.